FrancophonIA/ELRC3.0 huggingface dataset:
English: Sorbitan monooleate (E494) Titanium dioxide (E171) Vanillin.
Estonian: Sorbiinhape (E200) Sorbitaanmonooleaat (E494) Titaandioksiid (E171) Vanilliin
English: Pharmathen S.A., 6 Dervenakion Str., 15351 Pallini, Attiki, Greece
Estonian: Müügiloa hoidja ja tootja Pharmathen S.A, 6 Dervenakion Str., 15351 Pallini, Attiki, Kreeka.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 3. oktoober 2011
English: From a microbiological point of view, the product should be used immediately after dilution.
Estonian: Lähtuvalt mikrobioloogilistest nõuetest tuleb lahus kasutada otsekohe.
English: In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile.
Estonian: Võrreldes teiste vanusegruppidega teatati ohutusprofiili kokkuvõttes sagedamini 4...16aastastel lastel järgmistest kõrvaltoimetest: oksendamine (väga sage, 11,2%), agitatsioon (sage, 3,4%), meeleolu kõikumine (sage, 2,1%), labiilsus (sage, 1,7%), agressioon (sage, 8,2%), ebatavaline käitumine (sage, 5,6%) ja letargia (sage, 3,9%).
English: Tablet core: calcium hydrogen phosphate dihydrate, cellulose microcrystalline, crospovidone type A, hydroxypropylcellulose (L).
Estonian: Tableti sisu: kaltsiumvesinikfosfaatdihüdraat, mikrokristalne tselluloos, krospovidoon (A-tüüp), hüdroksüpropüültselluloos (L).
English: The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in fetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies.
Estonian: 1800 mg/kg ööpäeva annus põhjustas märkimisväärset toksilisust emasloomal ja loote kehakaalu langust koos loodete kardiovaskulaarsete/skeletimuutuste esinemise tõusuga.
English: Four embryo-fetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Estonian: Neljas embrüo-fetaalse arengu uuringus manustati küülikutele 200, 600, 800, 1200 ja 1800 mg/kg ööpäevas.
English: Then CLcr is adjusted for body surface area (BSA) as follows:
Estonian: Seejärel kohandatakse CLcr keha pindalale (BSA) järgnevalt: CLcr (ml/min)
English: There is no experience with administration of intravenous levetiracetam for longer period than 4 days.
Estonian: Ravi kestus Puuduvad andmed pikema kui 4 päeva kestva intravenoosse levetiratsetaam-ravi kohta.
English: Matever is indicated as adjunctive therapy
Estonian: Matever on näidustatud täiendava ravina:
English: Children from 4 years and adolescents weighing less than 50 kg
Estonian: Lapsed alates 4. eluaastast ja noorukid kehakaaluga alla 50 kg
English: The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, using the following formula:
Estonian: CLcr ml/min võib määrata seerumi kreatiniinisisalduse järgi (mg/dl) kasutades järgmist valemit täiskasvanutel ja noorukitel kehakaaluga üle 50 kg:
English: • There is no experience with administration of intravenous levetiracetam for a longer period than
Estonian: • Levetiratsetaami intravenoosse manustamise kohta pikema perioodi jooksul kui üle 4 päeva andmed puuduvad.
English: Each film-coated tablet contains 3.8 mg lactose monohydrate.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 3,8 mg laktoosmonohüdraati.
English: CLcr (ml/min/1.73 m 2) = ---------------------------- x 1.73 BSA subject (m
Estonian: CLcr (ml/min/1,73m 2) = -------------------------------- x 1,73 Keha pindala (m
English: The safety and efficacy of Matever concentrate for solution for infusion in infants and children less than 4 years have not been established.
Estonian: Matever infusioonilahuse kontsentraadi ohutus ja efektiivsus imikutel ja alla 4-aastastel lastel pole tõestatud.
English: If stopping treatment, as with other antiepileptic medicines, Matever should be discontinued gradually to avoid an increase of seizures.
Estonian: Kui te katkestate ravi ravimiga Matever, kui täiendava ravimiga, tuleb Matever ära jätta järk-järgult, et vältida krampide ägenemist.
English: quinoline yellow aluminium lake (E104)
Estonian: kinoliinkollane alumiiniumlakk (E104)
English: Intermediate packaging containing 100 tablets for multipack of 200 (2 x 100) tablets [without Blue Box]
Estonian: Üks sisepakendi karp sisaldab 100 tabletti, kokku on hulgipakendist 200 (2 x 100) tabletti [ILMA BLUE BOX'ITA]
English: 5 ml glass vial (type I) with bromobutyl stoppers and sealed with an aluminium flip off cap. Each cartoncontains10 vials.
Estonian: 5 ml klaasviaal (tüüp I), millel on bromobutüül sulgur ja see on kaetud alumiinium flip-off korgiga.
English: A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures.
Estonian: Topeltpimedas platseebokontrolliga laste mittehalvemusuuringus hinnati levetiratsetaami kognitiivseid ja neurofüsioloogilisi toimeid partsiaalsete krambihoogudega lastele (4…16-aastased).
English: • if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete levetiratsetaami, pürrolidooni derivaatide või selle ravimi mis tahes koostisosade
English: Matever concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25 °C.
Estonian: Matever kontsentraat on vähemalt 24 tunni jooksul füüsikaliselt sobiv ja keemiliselt stabiilne, kui seda segada järgmiste lahjendajate ja antiepileptiliste preparaatidega ja hoida PVC kottides kontrollitud temperatuuril 15…25°C.
English: Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Estonian: Levetiratsetaami efektiivsus tõestati 24-nädalase platseebokontrolliga topeltpimeuuringuga, mis kaasas idiopaatilist generaliseerunud epilepsiat põdevaid täiskasvanuid, noorukeid ja piiratud arvu lapsi, kellel erinevate sündroomidena (juveniilne müoklooniline epilepsia, juveniilne absaans-tüüpi epilepsia, lapsea absaans-tüüpi epilepsia, epilepsia grand mal hoogudega ärkveloleku ajal) esinesid primaarselt generaliseerunud toonilis-kloonilised krambid (PGTC).
English: 72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week.
Estonian: 72,2% levetiratsetaamiga ravitud patsientidest ning 45,2% platseebogrupi patsientidest saadi PGTCkrampide enam kui 50%-line vähenemine nädalas.
English: Children and adolescents • Matever is not indicated in children and adolescents below 16 years on its own (monotherapy).
Estonian: Lapsed ja noorukid • Matever ei ole näidustatud lastele ja alla 16-aastastele noorukitele ainsa ravimina.
English: Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg: General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.
Estonian: Annus lastele (4…11-aastased) ja noorukitele (12...17-aastased) kehakaaluga alla 50 kg Tavaline annus on vahemikus 20 mg/kehakaalu kg kohta kuni 60 mg/kehakaalu kg kohta iga päev.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Estonian: Täpne teave selle ravimpreparaadi kohta on Euroopa Ravimiameti (EMA) kodulehel http://www.ema.europa.eu
English: Peak plasma concentration (Cmax) observed in 17 subjects following a single intravenous dose of 1500 mg infused over 15 minutes was 51 ± 19 µg/ml (arithmetic average ± standard deviation).
Estonian: 17 isikul täheldati plasmakontsentratsiooni maksimumi (Cmax)51±19 µg/ml (aritmeetiline keskmine ± standardhälve), mis tekkis ühekordse intravenoosse annuse 1500 mg 15-minutilise infusiooni järgselt.
English: 500 mg tablet: quinoline yellow aluminium lake (E104) 750 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110) 1000 mg tablet: (no additional colourant).
Estonian: 500 mg tablett: kinoliinkollane alumiiniumlakk (E104) 750 mg tablett: indigokarmiinalumiiniumlakk (E132), päikeseloojangukollaneFCF (E110) 1000 mg tablett: (ei sisalda värvaineid).
English: • injury.
Estonian: • vigastused
English: How to take Matever
Estonian: Kuidas Matever'i kasutada
English: • as an add-on to other antiepileptic medicines to treat: partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Estonian: • patsientidel, kes juba võtavad mingit muud krambivastast ravimit generaliseerumisega või ilma partsiaalsete krambihoogude ravi täiskasvanutel, noorukitel ja lastel alates 1 kuu vanusest müoklooniliste krampide (lühiajalised šokitaolised lihaste või lihasrühmade tõmblused) raviks noorukiea müokloonilise epilepsiaga patsientidel alates 12 aasta vanusest primaarselt generaliseerunud toonilis-klooniliste krampide (rasked krambihood, millega kaasneb teadvusekaotus) ravis idiopaatilise generaliseerunud epilepsiaga täiskasvanutel ja noorukitel alates 12 aasta vanusest (epilepsia vorm, mille tekkepõhjust peetakse geneetiliseks).
English: What Matever is and what it is used for What you need to know before you take Matever How to take Matever
Estonian: Mis ravim on Matever ja milleks seda kasutatakse Mida on vaja teada enne Matever'i kasutamist Kuidas Matever'i kasutada Võimalikud kõrvaltoimed Kuidas Matever'i säilitada Pakendi sisu ja muu teave
English: In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days.
Estonian: Lastel (1 kuu...4-aastastel) tõestati levetiratsetaami efektiivsus platseebokontrolliga topeltpimeuuringus, mis hõlmas 116 patsienti ravi kestusega 5 päeva.
English: How to store Matever
Estonian: Kuidas Matever'i säilitada
English: The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications.
Estonian: Levetiratsetaami ohutuskokkuvõte on üldiselt sarnane kõigil vanusegruppidel ning kinnitatud epilepsia näidustuste korral.
English: Levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
Estonian: Levetiratsetaami suukaudset lahust kasutada annuses alla 250 mg, annuse korral ja olukorras, mil soovitatud annus ei ole saavutatav mitme 250 mg tableti koosmanustamisel ning patsientidel, kes ei ole võimelised tablette neelama.
English: 250 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110),
Estonian: 250 mg tablett: indigokarmiin alumiiniumlakk (E132), päikeseloojangu kollane FCF (E110),
English: For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
Estonian: 6-aastastel ja vanematel lastel kasutada levetiratsetaami suukaudset lahust alla 250 mg annuse korral ja olukorras, mil soovitatud annus ei ole saavutatav mitme 250 mg tableti koosmanustamisel ning patsientidel, kes ei ole võimelised tablette neelama.
English: CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA subject (m
Estonian: CLcr (ml/min/1,73m2) = --------------------------------- x 1,73
English: MARKETING AUTHORISATION NUMBER(S) EU/1/11/711/006
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/11/711/006
English: Matever therapy can be initiated with either intravenous or oral administration.
Estonian: Ravi levetiratsetaamiga võib teostada intravenoosselt või suukaudu manustatuna.
English: Diluents:
Estonian: Lahjendajad:
English: 6, Dervenakion EL-15351 Pallini Attiki Greece
Estonian: 6, Dervenakion Str. 153 51 Pallini Attiki, Kreeka
English: A large amount of post-marketing data on pregnant women exposed to levetiracetam monotherapy (more than 1,800, among which in more than 1,500 exposure occurred during the 1
Estonian: Turuletulekujärgselt levetiratsetaami monoteraapiana kasutanud rasedate kohta saadud suur hulk andmeid (rohkem kui 1800 raseda andmed, kellest rohkem kui 1500 kasutasid ravimit I trimestril) ei viita suurte kaasasündinud väärarengute suuremale riskile.
English: As with all antiepileptic medicinal products, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicinal products AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.
Estonian: Võimaluse korral tuleb eelistada monoteraapiat, sest ravi mitme epilepsiaravimiga võib sõltuvalt kasutatavatest epilepsiaravimitest olla seotud suurema kaasasündinud väärarengute riskiga kui monoteraapia.
English: Height (cm) x ks
Estonian: kasutades järgmist valemit (Schwartzi valem): Kehapikkus (cm) x ks
English: Matever 250 mg, 750 mg film-coated tablets contain E110 colouring agent which may cause allergic reactions.
Estonian: Matever 250 mg, 750mg õhukese polümeerikattega tabletid sisaldab värvainet päikeseloojangukollane FCF (E 110), mis võib põhjustada allergilist reaktsiooni.
English: In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg.
Estonian: Lisaks ei ole tabletid kohandatud kasutamiseks algannusena kehakaaluga alla 25 kg lastel, patsientidel, kellel on probleeme tableti neelamisega ning väiksemate annuste puhul kui 250 mg.
English: In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
Estonian: Lastel (4...16-aastastel) tõestati levetiratsetaami efektiivsus platseebokontrolliga topeltpimeuuringus, mis hõlmas 198 patsienti ravi kestusega 14 nädalat.
English: Matever 250 mg film-coated tablets Matever 500 mg film-coated tablets Matever 750 mg film-coated tablets Matever 1000 mg film-coated tablets
Estonian: Matever, 250 mg, õhukese polümeerikattega tabletid Matever, 500 mg, õhukese polümeerikattega tabletid Matever, 750 mg, õhukese polümeerikattega tabletid Matever, 1000 mg, õhukese polümeerikattega tabletid
English: The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections.
Estonian: Teised abiained on: naatriumatsetaattrihüdraat, jää-äädikhape, naatriumkloriid, süstevesi.
English: However, subjects who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behavior were not worse than baseline.
Estonian: Patsientidel, kes said levetiratsetaam-ravi avatud jätku-uuringus, ei täheldatud käitumuslike ja tundmuslike funktsioonide halvenemist; ülalmainitud kriteeriumide järgi ei olnud agressiivne käitumine halvenenud võrreldes algandmetega.
English: What you need to know before you are given Matever
Estonian: Mida on vaja teada enne kui teile manustatakse Matever'i Ärge kasutage Matever'i
English: Film-coating: hypromellose (E464), titanium dioxide (E171), hydroxypropyl cellulose (E463), propylene glycol (E1520), sorbic acid (E200), sorbitan monooleate (E494), vanillin, colourants*.
Estonian: Õhuke polümeerikate: hüpromelloos (E464), titaandioksiid (E171), hüdroksüpropüültselluloos (E463), propüleenglükool (E1520), sorbiinhape (E200), sorbitaanmonooleaat (E494), vanilliini, värvained*.
English: Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation
Estonian: Suitsiidi katse, suitsidaalne mõtlemine, psühhootiline häire, ebatavaline käitumine, hallutsinatsioonid, viha, segasus, paanikahoog, emotsionaalne labiilsus/meeleolu kõikumine, agiteeritus
English: Matever concentrate 5 ml vial is packed in a cardboard box of 10 vials.
Estonian: Matever kontsentraat: 5 ml viaal, kartongpakendis 10 viaali.
English: What you need to know before you take Matever
Estonian: Mida on vaja teada enne Matever'i kasutamist Ärge kasutage Matever'i
English: One vial contains 500 mg/5 ml levetiracetam.
Estonian: Üks viaal sisaldab 500 mg/5 ml levetiratsetaami.
English: Matever is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Estonian: Matever on näidustatud monoteraapiana partsiaalsete krambihoogude, sekundaarse generaliseerumisega või ilma, raviks esmaselt diagnoositud epilepsiaga patsientidel alates 16 aasta vanusest.
English: Calcium hydrogen phosphate dihydrate Microcrystalline cellulose Crospovidone type A Hydroxypropylcellulose (L)
Estonian: Kaltsiumvesinikfosfaatdihüdraat Mikrokristalliline tselluloos Krospovidoon (A-tüüp) Hüdroksüpropüültselluloos (L)
English: PHARMACEUTICALPARTICULARS
Estonian: Farmakodünaamilised toimed
English: België/Belgique/Belgien Pharmathen S.A.
Estonian: België/Belgique/Belgien
English: * The colourants are:
Estonian: Värvained on:
English: 100 film-coated tablets.
Estonian: 100 õhukese polümeerikattega tabletti.
English: Matever 1000 mg tablets contain lactose
Estonian: Matever 1000 mg tabletid sisaldab laktoosi.
English: The NOAEL was ≥ 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m basis).
Estonian: NOAEL (No Observed Adverse Effect Level) oli ≥ 1800 mg/kg ööpäevas F0 emasloomadel ja elulemus, kasv ja areng F1 pesakonnal vähene (6-kordne soovituslik maksimaalne päevane annus inimesel mg/m kohta).
English: Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m
Estonian: Seetõttu on soovitatav kreatiniini kliirensi korral <60 ml/min/1,73m2, ööpäevast säilitusannust vähendada 50%.
English: Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability
Estonian: Depressioon, vaenulikkus/ agressiivsus, ärevus, insomnia, närvilisus/ ärrituvus
English: Pancytopenia neutropenia, agranulocytosis
Estonian: Pantsütopeenia, neutropeenia, agranulotsütoos
English: Contains sunset yellow FCF aluminum lake (E110).
Estonian: Sisaldab värvainet päikeseloojangukollane FCF alumiiniumlakk (E110).
English: One tablet of Matever 1000 mg contains 1000 mg of levetiracetam.
Estonian: Üks Matever 1000 mg tablett sisaldab 1000 mg levetiratsetaami.
English: Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
Estonian: Dialüüsi järgselt on soovitatav manustada täiendavalt 3,5...7 mg/kg (0,035...0,07 ml/kg).
English: Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
Estonian: Dialüüsi järgselt on soovitatav manustada täiendavalt 5...10 mg/kg (0,05...0,10 ml/kg).
English: Matever is for intravenous use.
Estonian: Matever on intrevenoosseks manustamiseks.
English: • Dose in adults and adolescents (from 16 years of age): General dose: between 1,000 mg and 3,000 mg each day.
Estonian: • Annustamine täiskasvanutele ja üle 16-aastastele noorukitele: Tavaline igapäevane annus on 1000 mg kuni 3000 mg.
English: The 5 ml vial contains 500 mg of levetiracetam.
Estonian: 5 ml viaal sisaldab 500 mg levetiratsetaami.
English: One tablet of Matever 750 mg contains 750 mg of levetiracetam.
Estonian: Üks Matever 750 mg tablett sisaldab 750 mg levetiratsetaami.
English: Multipack: 200 (2 packs of 100) film-coated tablets
Estonian: Hulgipakend: 200 (2 pakendit, mis mõlemad sisaldavad 100) õhukese polümeerikattega tabletti
English: Each film-coated tablet contains 0.08 mg sunset yellow FCF aluminum lake (E110).
Estonian: Üks õhukese polümeerikattega tablett sisaldab 0,08 mg värvainet päikeseloojangukollane FCF alumiiniumlakk (E110).
English: The possible side effects of an overdose of Matever are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Estonian: Ravimi Matever üleannustamisel täheldati unisust, agiteeritust, agressiooni, teadvuse häireid, hingamise depressiooni ja koomat.
English: A doctor or a nurse will administer you Matever as an intravenous infusion.
Estonian: Matever'i manustatakse intravenoosse infusioonina arsti või õe poolt.
English: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
Estonian: Täiendravi müokloonsete krampidega täiskasvanutel ja juveniilse müokloonilise epilepsiaga noorukitel alates 12 aasta vanusest.
English: The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1200 mg/kg/day for fetuses.
Estonian: NOAEL (No Observed Adverse Effect Level) oli tiinetel emasrottidel 3600 mg/kg ööpäevas (mis vastab 12-kordsele soovituslikule maksimaalsele ööpäevasele annusele inimesel mg/m kohta) ja loodetel 1200 mg/kg ööpäevas.
English: Film-coating: hypromellose (E464), titanium dioxide (E171), talc, propylene glycol (E1520) colourants*.
Estonian: Õhuke polümeerikate: hüpromelloos (E464), titaandioksiid (E171), talk, propüleenglükool (E1520), värvained*.
English: One tablet of Matever 500 mg contains 500 mg of levetiracetam.
Estonian: Üks Matever 500 mg tablett sisaldab 500 mg levetiratsetaami.
English: Film-coating: hypromellose (E464), lactose monohydrate,macrogol/PEG 4000, titanium dioxide (E171).
Estonian: Õhuke polümeerikate: hüpromelloos (E464), laktoosmonohüdraat, makrogool/PEG 4000, titaandioksiid (E171).
English: • Lactated Ringer's injection
Estonian: • Ringer laktaadi süstelahus
English: Film-coating: hypromellose (E464), iron oxide red (E172), macrogol/PEG 4000, titanium dioxide (E171), colourants*.
Estonian: Õhuke polümeerikate: hüpromelloos (E464), punaneraudoksiid (E172), makrogool/PEG 4000, titaandioksiid (E171), värvained*.
English: The safety and efficacy of Matever in children and adolescents below 16 years as monotherapy treatment have not been established.
Estonian: Ravimi Matever monoteraapia ohutus ja efektiivsus lastel ja alla 16-aastastel noorukitel pole tõestatud.
English: Contains glacial acetic acid, water for injections, sodium acetate trihydrate, sodium chloride - see leaflet for further information.
Estonian: Sisaldab jää-äädikhapet, süstevett, naatriumatsetaattrihüdraati, naatriumkloriidi.
English: Box of 10 vials
Estonian: Üks karp sisaldab 10 viaali.
English: A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.
Estonian: Soovitatav on ravi esimesel päeval kasutada algannust 15 mg/kg (0,15 ml/kg) levetiratsetaami.